Intervention not reported
AFP (cut‐off 20 ng/mL) · adults with chronic liver disease
1 finding from 1 review
Intervention not reported
AFP (cut‐off 200 ng/mL) · adults with chronic liver disease
1 finding from 1 review
Intervention not reported
US · adults with chronic liver disease
1 finding from 1 review
Intervention not reported
Combination of AFP (cut‐off 20 ng/mL) and US · adults with chronic liver disease
1 finding from 1 review
Intervention not reported
US · adults with chronic liver disease
1 finding from 1 review
Intervention not reported
Combination of AFP (cut‐off 20 ng/mL) and US · adults with chronic liver disease
1 finding from 1 review
Intervention not reported
CT · adults with chronic liver disease
1 finding from 1 review
Intervention not reported
CT · adults with chronic liver disease
1 finding from 1 review
Mortality at 8 weeks · adults living with HIV
Effect of LF‐LAM probably leads to lower mortality at 8 weeks compared with no LF‐LAM on mortality and tuberculosis treatment initiation (moderate certainty).
1 finding from 1 review
People started on tuberculosis treatment · adults living with HIV
Effect of LF‐LAM showed no clear difference in people started on tuberculosis treatment compared with no LF‐LAM on mortality and tuberculosis treatment initiation (moderate certainty).
2 findings from 1 review
Mortality at 6 months · adults living with HIV
Effect of LF‐LAM showed no clear difference in mortality at 6 months compared with no LF‐LAM on mortality and tuberculosis treatment initiation (low certainty).
1 finding from 1 review
Failure to induce global or clinical remission · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA leads to lower failure to induce complete global or clinical remission compared with placebo (high certainty).
1 finding from 1 review
Failure to induce endoscopic remission · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to adhere to medication regimen · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA probably leads to lower adverse events compared with SASP (moderate certainty).
1 finding from 1 review
Serious adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in serious adverse events compared with SASP (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA probably leads to lower withdrawal due to adverse events compared with SASP (moderate certainty).
1 finding from 1 review
Failure to induce global or clinical remission · Patients with active mild to moderate ulcerative colitis
Once daily dosing showed no clear difference in failure to induce global or clinical remission compared with conventional dosing (high certainty).
1 finding from 1 review
Failure to induce global or clinical improvement · Patients with active mild to moderate ulcerative colitis
Once daily dosing showed no clear difference in failure to induce global or clinical improvement compared with conventional dosing (moderate certainty).
1 finding from 1 review
Failure to induce endoscopic remission · Patients with active mild to moderate ulcerative colitis
Once daily dosing showed no clear difference in failure to induce endoscopic remission compared with conventional dosing (high certainty).
1 finding from 1 review